BIOARTIFICIAL ORGANS III--TISSUE/IMMUNOISOLATION/TRIALS

描述（取自应用程序） 一个会议，“生物人工器官III：组织来源，免疫隔离和 临床试验”，拟于2000年10月7日至11日在达沃斯举行， 瑞士），探索当代和新兴的生物人工方法， 当它们与不同的场相互作用时。生物医学应用和 将突出临床试验。目的是充分利用 跨学科方法：化学，物理化学，材料科学， 高分子化学，细胞培养，重组DNA技术，生物过程 工程和临床科学。具体而言，它将汇集三个 通常不在一次会议上互动的专业人员群体： (1)材料和聚合物科学家，（2）生物工艺工程师，和（3）医疗 专业人士重点将放在这些学科的交叉部分。 主要覆盖范围将在胰腺，肝脏，肾脏，皮肤，牙齿和骨骼 地区该计划将强调科学基础， 申请并审查每个领域的临床状况。将尝试 使其在聚合物中具有约2SM 5/50的百分比分配， 工程和生物医学类。此外，组织者 预计参与者将来自学术界，工业界和临床 机构基本持平。一个强有力的代表 美国的应急措施对继续进行多学科合作至关重要， 生物人工器官系列的培育。这一点在2000年尤为突出， 许多美国大学、医疗中心和公司正在与全球 合作伙伴或赞助商将生物人工器官从研究转移到临床 和市场作为评估新设备所需的参数和指标 和治疗方法正在开发中。监管者、高管的参与 以及来自大型中小型企业和 包括会前生物技术投资者峰会， 程序.会议将具有戈登会议的风格。联合 工程基金会（纽约）将承担主要责任， 行政、后勤、机械、宣传、房屋和财政 会议资金支持要求NIH，NSF，Whitaker Fdn.， 青少年糖尿病基金会，FNS（瑞士）、欧洲联盟和其他 源会议记录将作为同行评议的 卷（纽约科学院）。

DESCRIPTION (taken from the application) A conference, "Bioartificial Organs III: Tissue Sourcing, Immunoisolation and Clinical Trials," is proposed for October 7-11, 2000 (to be held in Davos, Switzerland), to explore contemporary and emerging approaches of bioartificial organs as they interface with different fields. Biomedical applications and clinical trials will be highlighted. The intent is to make use of a fully interdisciplinary approach: chemistry, physical chemistry, materials science, polymer chemistry, cell culture, recombinant DNA technology, bioprocess engineering, and clinical sciences. Specifically, it will bring together three groups of professionals, who do not normally interact at a single conference: (1) materials and polymer scientists, (2) bioprocess engineers, and (3) medical professionals. The emphasis will be at the cross-section of these disciplines. The main coverage will be in the pancreas, liver, kidney, skin, dental and bone areas. The program will stress scientific fundamentals, evolve into applications and review the clinical status in each area. An attempt will be made to have approximately 2SM5/50 percentage split amongst the polymer, engineering and biological-medical categories. In addition, the organizers expect that the participants will come from academia, industry and clinical institutions on approximately even basis. The representation of a strong American contingency is critical to continue the multidisciplinary, which the bioartifical organ series has fostered. This is particularly acute In 2000 as a number of US universities, medical centers and firms am integrating with global partners or sponsors to move bioartificial organs from research to the clinic and marketplace as the parameters and metrics needed to evaluate new devices and therapies are being developed. The participation of regulators, executives and research directors from large small and medium sized enterprises and the inclusion of a pre-conference biotechnology investors summit complements the program. The conference will have a Gordon Conference style. The United Engineering Foundation (New York) will assume primary responsibilities for administration, logistics, mechanics, publicity, housing, and finance for the conference. The funding support is requested from NIH, NSF, Whitaker Fdn., Juvenile Diabetes Fdn., FNS (Switzerland), European Union and from other sources. The proceedings of the conference will be published as a peer reviewed volume (The New York Academy of Sciences).